IBM Dives into the Life Sciences
IBM thinks that the life sciences industry, where it has had little presence to date, is now big enough and ripe enough to be worth pursuing. It aims to get in at the start of the value chain via bioinformatics. The computing giant has bigger plans than smaller players that moved earlier to focus on bioinformatics-and it has the means to see them through. Pioneers got stuck doing fee-for-service work, but IBM can sell Big Pharmas hardware, software and most importantly, all sorts of services. IBM's debut product in life sciences is DiscoveryLink, which lets data from disparate sources be queried as though they were all in one, giant database. It's also meant to broadly support software created by specialized applications developers. Installations will have to be custom jobs-ideally, part of bigger IT contracts. Other computing concerns also perceive opportunity in life sciences; indeed it's clear a battle is brewing between big hardware suppliers. But they're cooperating to a degree: calling for data standards, so they can compete on products not technology. IBM has credibility from other sectors, but it's uncertain how applicable it expertise will be in life sciences, even if it can find and train enough people. Also unclear: whether drugmakers actually want and will pay big money for integrated solutions. Though a newcomer to life sciences, IBM may be uniquely suited to serve the industry-not only because of its own deep and ongoing research into computational biology, but because it can offer drugmakers one-stop shopping.
You may also be interested in...
VCs worried about depressed financial markets and demanding Big Pharma customers are being tough on almost all start-ups seeking funding-but no tougher than on their existing portfolio companies. For some, hard times are creating opportunities. The circumstances of companies that raised money in the past few years are impacting newer firms now. Even organizations that met their milestones have seen valuations plummet, and are struggling to get financing. The down market is making it more desirable and easier for VCs to invest in late-stage start-ups. In-licensing has been popular, but investors are increasingly seeking value-priced components to fill out existing firms or launch new ones. Investors haven't stopped doing early-stage deals, but they're looking for firms with advantages that can reduce risk or cost, or speed a company to market. Drugmakers that used to sign big-money deals are now demanding that start-ups prove their technologies' merits through short-term, inexpensive pilot programs. Some firms aren't so pressed by hard times. VCs are promising stellar founders lots of support and time to take big risks they bet will pay off handsomely.
Proteomics companies don't want to be seen as database providers, a low-valuation model once pursued by Celera and Incyte. So companies like Myriad Genetics and Oxford GlycoSciences have spun out their database businesses into JVs with IT partners, which provide cash and technology. Both partners benefit: biotechs get valued as budding drug developers and retain access to these tools, while IT companies get a foot in the door of the life sciences markets into which they wish to expand their products and services.
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.